Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Janssen Pharmaceutical has asked the U.S. Food and Drug Administration (FDA) to approve the use of intravenous Uptravi (selexipag) by pulmonary arterial hypertension (PAH) patients unable for a given time to use Uptravi ... Read more
Delayed diagnosis, limited resources, and a lack of awareness compound barriers to care for people with pulmonary hypertension (PH) in low- and middle-income countries, a recent review found. The ... Read more
Using sildenafil and milrinone together proved more effective than either therapy alone in treating newborns with severe persistent pulmonary hypertension (PH), a recent clinical study indicates. This combo treatment ... Read more
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient ... Read more
High levels of the peptide adiponectin show potential as a biomarker for the prognosis of congenital heart disease in patients with pulmonary hypertension (PH), according to a recent study. Titled ... Read more
Aerovate Therapeutics received $72.6 million in Series A funding to advance trials testing AV-101, an experimental inhaled version of imatinib for the treatment of pulmonary arterial hypertension (PAH). AV-101 is ... Read more
Pregnant women with pulmonary arterial hypertension (PAH) should seek specialist care before giving birth and for months afterward, due to the risk of severe maternal complications and high rates ... Read more